首页> 外文OA文献 >Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkinrsquo;s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey Corrigendum

【2h】

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkinrsquo;s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey Corrigendum

机译：基于系统调查的17名意大利医院在非霍奇金淋巴瘤中皮下与静脉内泌尿外静脉静脉静脉施用的潜在资源和成本节约分析。基于系统调查勘误

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Clemente Ponzetti; Monica Canciani; Massimo Farina; Sara Era; Stefan Walzer;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum] [J] . ClinicoEconomics and Outcomes Research . 2017,第10期

机译：基于系统性调查，意大利17家医院的非霍奇金淋巴瘤皮下注射和静脉注射利妥昔单抗和乳腺癌曲妥珠单抗的潜在资源和成本节省分析[勘误]
2. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [J] . Clemente Ponzetti, Monica Canciani, Massimo Farina, ClinicoEconomics and Outcomes Research . 2016,第67期

机译：基于系统性调查，在意大利的17家医院中，皮下注射和静脉注射利妥昔单抗治疗非霍奇金淋巴瘤和曲妥珠单抗治疗乳腺癌的潜在资源和成本节省分析
3. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands [J] . Margreet G. Franken, Tim A. Kanters, Jules L. Coenen, Anti-cancer drugs . 2018,第8期

机译：由于肿瘤药物施用途径的潜在成本：荷兰静脉和皮下施用曲妥珠单抗和拉特昔单抗的微观研究
4. Cost-Benefit Analysis of Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel for the Treatment of Metastatic Breast Cancer in the United States [D] . Vichansavakul, Kittaya 2013

机译：纳米白蛋白结合紫杉醇与溶剂型紫杉醇在美国治疗转移性乳腺癌的成本效益分析
5. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey Corrigendum [O] . 2017

机译：基于系统调查皮下注射或静脉注射利妥昔单抗治疗非霍奇金淋巴瘤和曲妥珠单抗治疗乳腺癌的潜在资源和成本分析在意大利的17家医院中更正
6. PCN203 Resource And Cost Savings Due To Subcutaneous Versus Intravenous Administration Of Oncology Therapies: Case Studies With Rituximab (Mabthera) And Trastuzumab (Herceptin) [O] . Walzer S, Era S, Profico A, 2015

机译：皮下注射与肿瘤治疗的静脉内给药相比可节省PCN203的资源和成本：利妥昔单抗（Mabthera）和曲妥单抗（Herceptin）的案例研究

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkinrsquo;s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey Corrigendum

著录项

引文网络

相似文献

相关主题

期刊订阅